NFL Biosciences SA and ATHENA Pharmaceutiques announced that they have set up a co-development agreement. ATHENA Pharmaceutiques will manage the development and manufacturing of NFL-301, a natural drug candidate from NFL Biosciences aimed at reducing alcohol consumption, while NFL Biosciences will draw up and lead the clinical program. The partnership between NFL Biosciences and ATHENA Pharmaceutiques will involve developing NFL-301 at least until its placebo-controlled efficacy has been demonstrated as a treatment for reducing alcohol consumption.

A proof of concept clinical trial application could be submitted in 2022 in the United States. NFL Biosciences and ATHENA Pharmaceutiques will make a joint investment and will share future revenues based on their respective investments. NFL-301 has a unique positioning because it is a natural drug candidate and it aims to help people reduce their alcohol consumption and particularly binge drinking episodes.